

Product datasheet for **TF317417**

CARD9 Human shRNA Plasmid Kit (Locus ID 64170)

Product data:

Product Type:	shRNA Plasmids
Product Name:	CARD9 Human shRNA Plasmid Kit (Locus ID 64170)
Locus ID:	64170
Synonyms:	caspase recruitment domain family, member 9; caspase recruitment domain protein 9; hCARD9; OTTHUMP00000022571
Vector:	pRFP-C-RS (TR30014)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	CARD9 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID = 64170). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.
RefSeq:	NM_022352 , NM_052813 , NM_052814 , NM_052813.1 , NM_052813.2 , NM_052813.3 , NM_052813.4 , NM_052814.1 , NM_052814.2 , NM_052814.3 , BC008877 , BC035805 , BM148244 , NM_052814.4 , NM_052813.5
UniProt ID:	Q9H257
Summary:	The protein encoded by this gene is a member of the CARD protein family, which is defined by the presence of a characteristic caspase-associated recruitment domain (CARD). CARD is a protein interaction domain known to participate in activation or suppression of CARD containing members of the caspase family, and thus plays an important regulatory role in cell apoptosis. This protein was identified by its selective association with the CARD domain of BCL10, a positive regulator of apoptosis and NF-kappaB activation, and is thought to function as a molecular scaffold for the assembly of a BCL10 signaling complex that activates NF-kappaB. Several alternatively spliced transcript variants have been observed, but their full-length nature is not clearly defined. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).